Sonex Health, a MN-based company which specializes in the ultrasound-guided treatment of common orthopedic syndromes affecting the extremities, raised USD40M in Series B funding.
The round was led by KCK MedTech.
In conjunction with this Series B financing, the company also closed on a new debt facility with venture leader Horizon Technology Finance Corporation.
The company intends to use the funds to expand access of its commercially available devices that use ultrasound guidance to safely and effectively treat patients suffering from the debilitating pain caused by carpal tunnel syndrome (CTS) and trigger finger (TF) and allow those patients to rapidly return to normal activities.
Led by Bob Paulson, president and CEO, Sonex Health is a leader in innovative ultrasound-guided therapies to treat common orthopedic conditions affecting the extremities, including entrapment neuropathies and tendinopathies. The company’s proprietary devices allow surgeons to use real-time ultrasound guidance to visualize critical anatomy throughout procedures, thereby reducing both invasiveness and the cost of care, and enabling patients to return to their normal activities sooner. The company’s first commercial device, UltraGuideCTR™, was designed to treat carpal tunnel syndrome and received FDA clearance in 2019. The company’s second commercial device, UltraGuideTFR™ was designed to treat trigger finger, also known as stenosing tenosynovitis, and was released in 2022.
FinSMEs
15/09/2023